Katherine D. Crew, discusses the results of HER2CLIMB and DESTINY-Breast01, as well as other impactful data in HER2-positive breast cancer that emerged from the 2019 San Antonio Breast Cancer Symposium.
Original Article: SABCS Showcased Novel Agents in the HER2+ Breast Cancer Armamentarium